Vision Support II is a combination of the most advanced nutrients clinically demonstrated to help support eye health and fight age-related macular degeneration (AMD). AOR’s Vision Support II provides lutein, zeaxanthin, benfotiamine and black soybean hull extract in an olive oil suspension to enhance the absorption of these ingredients. The effectiveness of Vision Support II can be maximized with a complete, high-quality multivitamin/mineral formulation.
Vision Support II is primarily designed to protect against age-related macular degeneration (AMD), and can also protect against the development of cataracts. Ultraviolet light and blue light contribute to damage in the lens and macula, and lutein and zeaxanthin are pigments found in the eyes whose main function is the filtration of UV light. Benfotiamine is a highly bioavailable form of vitamin B1, and studies have shown that it helps prevent the formation of AGEs (advanced glycation end-products), which are damaged proteins that accumulate in the lens and can result in cataracts.
Overall, Vision Support II is especially beneficial for those with a family history of macular degeneration, those with cataracts, for active people who spend a lot of time outside in the sun, and for those at risk of computer vision syndrome such as office workers or students.
AOR’s Vision Support II formula includes a variety of nutrients that have a positive impact on eye health. These ingredients are delivered in an oil-based delivery system for improved absorption.
AOR™ guarantees that all ingredients have been declared on the label. Contains no wheat, gluten, nuts, peanuts, sesame seeds, mustard, dairy, eggs, fish or shellfish.
Take two softgels per day with food, or as directed by a qualified health care practitioner.
Consult a health care practitioner prior to use if you are pregnant, breastfeeding, taking blood thinners or for use beyond four weeks. Contains soy and corn, do not use if you have these allergies.
Non-medicinal Ingredients: extra virgin olive oil, medium chain triglycerides, safflower oil, corn oil, mixed tocopherol concentrate. Softgel: gelatin, caramel and glycerin.
The information and product descriptions appearing on this website are for information purposes only, and are not intended to provide or replace medical advice to individuals from a qualified health care professional. Consult with your physician if you have any health concerns, and before initiating any new diet, exercise, supplement, or other lifestyle changes.
This maritime carotenoid has distinguished itself in recent years in a number of roles, one of which is asthenopia. This increasingly common condition is often caused by overexposure to visual display terminals (VDT’s), and human studies have shown that astaxanthin can alleviate asthenopia symptoms (such as eye strain, redness, and blurred vision) by 54%. Scientists believe the mechanism of action for these benefits is based on the increased ciliary body accommodation, increased retinal blood flow, and anti-inflammatory properties associated with astaxanthin supplementation. The ciliary body is composed primarily of an ocular muscle that stretches across the vitrous humour between the lens and the pupil. Accomodation refers to the ability of the ciliary body to manipulate the thickness of the lens in order to focus light on the retina. If the eye is required to focus on a fixed object for extended periods of time, muscle spasms and other signs of fatigue may occur. Factors such as the speed at which the ciliary body reacts to a change in visual focus are used to evaluate improvements (if any) in the accommodation response. Two clinical studies conducted in 2005 determined that the speed of the ciliary body’s reactions in the astaxanthin group were approximately 46% faster than those in the placebo group. This means that those taking astaxanthin were able to spot moving objects that much faster than those who were not. Furthermore, another placebo-controlled clinical study determined that astaxanthin can increase retinal blood flow by approximately 11% while yet another study (with laboratory rats) found that astaxanthin can reduce ciliary cell inflammation by nearly 80%.
Black Soybean Hull Extract
Asthenopia can arguably be considered part of the information age since it is so closely associated with overexposure to visual display terminals (VDTs). Nowhere is this reality more acute than in Japan, home of the most automated economy in the world. It seems fitting, therefore, that so many of the latest clinical studies dealing with Asthenopia originate there. The aforementioned astaxanthin clinical studies are one example, and those concerning black soybean hull extract are another. One such study in 2004 demonstrated black soybean hull extract ‘significantly’ improved the symptoms of Asthenopia among 32 healthy adults who regularly engage in VDT work. Black soybean hull extract is another example of ‘pushing the envelope’ to develop the most advanced ocular health nutraceuticals possible.
Very simply put, glycation is the bonding of sugar molecules to proteins or lipids in the body without the mediating action of an enzyme or coenzyme, and is a natural part of the aging process. The end result is the formation of Advanced Glycation Endproducts (AGEs) – stiff tissue that can affect any cell in the body. The cells of the retina are particularly vulnerable, because when blood sugar levels rise, some key cells high in metabolic activity (such as the retina cells and the filtering cells [glomeruli] of the kidney) are flooded with glucose. Thiamin pyrophosphate (TPP) is the active coenzyme form of thiamin, and maintaining high TPP levels will cause an enzymatic reaction that alleviates the effects of this glucose backlog, thus inhibiting the formation of AGEs. Benfotiamine is a lipid-soluble version of thiamin that is at least 5 times more bioavailable than regular thiamin supplements, and is the most efficient method known for effectively raising TPP levels in body tissues other than the brain.
Lutein and Zeaxanthin
This ‘dynamic duo’ of ocular health is by no means new. In nature, these are pigments that give vegetables such as corn and spinach their color, but in the human body, these are fat-soluble carotenoids (structurally similar to vitamin A) that are found primarily in the retina. This fact has always served to define their antioxidant capacities specifically within the realm of ocular health, with clinical and observational studies demonstrating their effectiveness in dealing with the symptoms of Age-Related Macular Degeneration (AMD) and cataract formation. AMD refers to the age-related deterioration of the central part of the retina (namely the macula), which is adjacent to the optic nerve and contains the fovea, which is at the center of the macula and is responsible for detailed central vision. Like glycation, AMD is a normal part of the aging process and can vary greatly in degrees of severity. Prevention is key of course, and the latest clinical studies using lutein and zeaxanthin have taken an unmistakable trend: the dosages have been increasing and more emphasis has been made on absorption. Indeed, one very encouraging study used 30 mg daily of both lutein and zeaxanthin (in a base of canola oil) to raise macular pigment optical density(OD) in healthy human subjects by as much as 40% in a dose-dependent manner.